Cancers, Free Full-Text

As lung cancer has the highest cancer-specific mortality rates worldwide, there is an urgent need for new therapeutic and diagnostic approaches to detect early-stage tumors and to monitor their response to the therapy. In addition to the well-established tissue biopsy analysis, liquid-biopsy-based assays may evolve as an important diagnostic tool. The analysis of circulating tumor DNA (ctDNA) is the most established method, followed by other methods such as the analysis of circulating tumor cells (CTCs), microRNAs (miRNAs), and extracellular vesicles (EVs). Both PCR- and NGS-based assays are used for the mutational assessment of lung cancer, including the most frequent driver mutations. However, ctDNA analysis might also play a role in monitoring the efficacy of immunotherapy and its recent accomplishments in the landscape of state-of-the-art lung cancer therapy. Despite the promising aspects of liquid-biopsy-based assays, there are some limitations regarding their sensitivity (risk of false-negative results) and specificity (interpretation of false-positive results). Hence, further studies are needed to evaluate the usefulness of liquid biopsies for lung cancer. Liquid-biopsy-based assays might be integrated into the diagnostic guidelines for lung cancer as a tool to complement conventional tissue sampling.

Game Rong Den 5 Get File - Colaboratory

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Precision cancer medicine: Concepts, current practice, and future developments - Edsjö - 2023 - Journal of Internal Medicine - Wiley Online Library

Hallmarks of Cancer: The Next Generation: Cell

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study - The Lancet Oncology

Cancers, Free Full-Text

Cancers, Free Full-Text

Cancers, Free Full-Text

Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization